Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Images Show Serotonin-activating its Receptor for First Time

By Case Western Reserve University | November 2, 2018

Serotonin-induced activation of serotonin (3A) receptors. Photo: CWRU

Serotonin (3A) receptors are common drug targets in the treatment of pain, gastrointestinal dysfunctions, and mood disorders yet little is known about their three-dimensional structure. Details about serotonin receptor structures could provide important clues to designing better drugs with less side effects. Now, a team of researchers from Case Western Reserve University School of Medicine have used high-powered microscopes to view serotonin activating its receptor for the first time. Images published in Nature reveal molecular details about the receptor that could improve drug design to treat a multitude of diseases.

Serotonin receptors sit in cell membranes throughout the body, including the brain, stomach, and the associated nervous system. Drugs that inhibit serotonin receptors help control post-operative nausea, support cancer therapies, and are used to treat gastrointestinal conditions like irritable bowel syndrome. These inhibitors also find application as anti-depressants, and promote attention and memory.

Broad application comes with side effects—in part due to suboptimal drug-receptor interactions, says study lead Sudha Chakrapani, PhD, associate professor of physiology and biophysics at Case Western Reserve University School of Medicine. “Successful design of safer therapeutics has been slowed because there is a limited understanding of the structure of the serotonin receptor itself, and what happens after serotonin binds to it. Our work is the first to describe how serotonin activates the full-length serotonin receptor at a level of detail to nearly the individual atom.”

Using Nobel Prize-winning microscope technology, Chakrapani’s team studied serotonin as it interacted with its receptor. Their images show serotonin attaching to the receptor and twisting open the channel. Open channels allow molecules to travel from outside the cell to inside. The researchers used simulations to watch as sodium molecules traveled through newly opened channels. The new study highlights distinct conformations of the serotonin receptor that would make a cell more or less permeable to certain molecules—a key insight for drug developers. It also shows which portions of the receptor are most critical for proper channel function.

The entire serotonin-receptor occurs in a space about a few billionths of a meter across. Microscopes have only recently evolved to capture such tiny molecules. Cutting-edge technology in the new study—cryo-electron microscopy—earned a 2017 Nobel Prize in chemistry. It uses high-powered microscopes to take snapshots of proteins in action, and compiles them into three-dimensional structural models. In the past year it has already helped Case Western Reserve researchers view structures for proteins central to kidney stones and other ailments. Chakrapani used “cryo-EM” last year to view the serotonin receptor alone, laying the foundation for the present study.

The researchers hope their findings could lead to more precise drugs that target specific regions or functions of serotonin receptors. “It’s likely that new and different drugs can work as effective serotonin inhibitors, especially if they’re designed to work differently than current drugs,” says first author Sandip Basak, PhD, postdoctoral fellow in Chakrapani’s lab. “We’re actively pursuing these approaches to help design safer therapeutics that modulate the serotonin receptor to treat a range of conditions.”


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE